ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Acquired by Prudential Financial Inc.

Prudential Financial Inc. increased its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 1.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 524,430 shares of the biotechnology company’s stock after buying an additional 5,897 shares during the quarter. Prudential Financial Inc. owned about 0.22% of ADMA Biologics worth $8,994,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ADMA. Larson Financial Group LLC purchased a new position in shares of ADMA Biologics in the 3rd quarter valued at $31,000. GAMMA Investing LLC raised its position in ADMA Biologics by 106.6% in the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 967 shares during the period. National Bank of Canada FI acquired a new position in shares of ADMA Biologics during the third quarter worth about $35,000. Vision Financial Markets LLC purchased a new stake in shares of ADMA Biologics in the fourth quarter worth about $51,000. Finally, AlphaQuest LLC acquired a new stake in shares of ADMA Biologics in the fourth quarter valued at about $84,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

ADMA stock opened at $20.26 on Friday. The company has a market capitalization of $4.79 billion, a P/E ratio of 72.36 and a beta of 0.60. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The company has a 50-day simple moving average of $17.13 and a 200 day simple moving average of $18.15. ADMA Biologics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $23.64.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.